Literature DB >> 20876670

Water prescription in autosomal dominant polycystic kidney disease: a pilot study.

Connie J Wang1, Catherine Creed, Franz T Winklhofer, Jared J Grantham.   

Abstract

BACKGROUND AND OBJECTIVES: In animal models of polycystic kidney disease, the ingestion of large amounts of water promotes diuresis by suppressing plasma levels of arginine vasopressin (AVP) and renal levels of cAMP, slowing cyst progression. Whether simple water ingestion is a potential therapeutic strategy for individuals with autosomal dominant polycystic kidney disease (ADPKD) is unknown. In this study, a simple method to quantify the amount of water to achieve a specific mean urine osmolality target in patients with ADPKD was developed and tested. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In eight ADPKD patients eating typical diets, osmolality and volume were measured in 24-hour urine collections. The amount of additional ingested water required daily to achieve a mean urine osmolality of 285 ± 45 mosm/kg was determined. Participants were instructed to distribute the prescribed water over waking hours for each of 5 days. Blood chemistries, 24-hour urine collections, BP, and weight were measured before and after the period of supplemental water intake.
RESULTS: Five patients achieved the 285 mosm/kg urine target without difficulty. Mean urine osmolality decreased and mean urine volume increased; serum sodium, weight, and BP were unchanged. Daily osmolar excretion remained constant, indicating a stable ad lib dietary intake of solutes and protein over the 2-week study period.
CONCLUSIONS: The amount of additional water needed to achieve a urine osmolality target can be approximated from the urine osmolar excretion in ADPKD patients eating typical diets, providing a quantitative method to prescribe supplemental water for such individuals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876670      PMCID: PMC3022242          DOI: 10.2215/CJN.03950510

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  22 in total

1.  Increased water intake decreases progression of polycystic kidney disease in the PCK rat.

Authors:  Shizuko Nagao; Kazuhiro Nishii; Makoto Katsuyama; Hiroki Kurahashi; Tohru Marunouchi; Hisahide Takahashi; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2006-06-28       Impact factor: 10.121

2.  Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.

Authors:  V H Gattone; R L Maser; C Tian; J M Rosenberg; M G Branden
Journal:  Dev Genet       Date:  1999

3.  The clinical utility of renal concentrating capacity in polycystic kidney disease.

Authors:  P A Gabow; W D Kaehny; A M Johnson; I T Duley; M Manco-Johnson; D C Lezotte; R W Schrier
Journal:  Kidney Int       Date:  1989-02       Impact factor: 10.612

4.  Short- and long-term biological variation in analytes in urine of apparently healthy individuals.

Authors:  M D Shephard; L A Penberthy; C G Fraser
Journal:  Clin Chem       Date:  1981-04       Impact factor: 8.327

5.  Biological variation in analyte concentrations in urine of apparently healthy men and women.

Authors:  E M Gowans; C G Fraser
Journal:  Clin Chem       Date:  1987-06       Impact factor: 8.327

6.  Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.

Authors:  Vincent H Gattone; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

Review 7.  Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach.

Authors:  Jared J Grantham
Journal:  Kidney Int       Date:  2003-10       Impact factor: 10.612

Review 8.  Urine volume: stone risk factor and preventive measure.

Authors:  L Borghi; T Meschi; T Schianchi; A Briganti; A Guerra; F Allegri; A Novarini
Journal:  Nephron       Date:  1999       Impact factor: 2.847

9.  Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study.

Authors:  L Borghi; T Meschi; F Amato; A Briganti; A Novarini; A Giannini
Journal:  J Urol       Date:  1996-03       Impact factor: 7.450

10.  Biological variation in urine samples used for analyte measurements.

Authors:  C Ricós; C V Jiménez; A Hernández; M Simón; C Perich; V Alvarez; J Minchinela; M Maciá
Journal:  Clin Chem       Date:  1994-03       Impact factor: 8.327

View more
  35 in total

Review 1.  Rationale for early treatment of polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  Pediatr Nephrol       Date:  2014-07-15       Impact factor: 3.714

Review 2.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

Review 3.  Autosomal dominant polycystic kidney disease in children.

Authors:  Melissa A Cadnapaphornchai
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

4.  Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Authors:  Olivier Devuyst; Arlene B Chapman; Ron T Gansevoort; Eiji Higashihara; Ronald D Perrone; Vicente E Torres; Jaime D Blais; Wen Zhou; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

Review 5.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

6.  Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis.

Authors:  Oliver Oey; Padmashree Rao; Magdalena Luciuk; Carly Mannix; Natasha M Rogers; Priyanka Sagar; Annette Wong; Gopala Rangan
Journal:  Exp Biol Med (Maywood)       Date:  2018-02-13

Review 7.  ADPKD current management and ongoing trials.

Authors:  Francesca Testa; Riccardo Magistroni
Journal:  J Nephrol       Date:  2019-12-18       Impact factor: 3.902

Review 8.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

9.  Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.

Authors:  Osama W Amro; Jessica K Paulus; Farzad Noubary; Ronald D Perrone
Journal:  Am J Kidney Dis       Date:  2016-09-20       Impact factor: 8.860

Review 10.  Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.

Authors:  Markus M Rinschen; Bernhard Schermer; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.